Genmab- NEUTRAL
GNMSF; DKK 245.00; C-2-9
Genmab: ASH cancer meeting preview
Detailed data for Genmab's CD20 antibody will be presented at the ASH cancer
meeting on Monday evening (8 December). This is Genmab's lead product which
could be filed within the coming weeks/months and launched in the US next year
with marketing partner GSK.
Impressive headline clinical data for the anti-CD20 antibody in refractory CLL (a
blood cancer) were released in July, and we saw more details when the meeting
abstracts were published last month. Despite some safety signals, the risk/benefit
profile appears favourable taking into account these patients’ late-stage disease,
so the outlook is so far positive for product approval.
We are looking for the following information at ASH which could improve our
outlook for Genmab's CD20: (1) strong efficacy in patients previously exposed to
the commonly used CD20 antibody Rituxan; (2) similar efficacy in patients from
different geographic regions; (3) good duration of response (at least 3-4 months);
and (3) endorsement from clinicians regarding broad use of Genmab's antibody in
other blood cancers despite the safety signals revealed in the current study.
A positive view from clinicians would support our CD20 peak sales forecast of
over $2bn across multiple disease indications.
Erica Whittaker >>
Research Analyst, MLPF&S (UK)
+44 20 7996 2408
GNMSF; DKK 245.00; C-2-9
Genmab: ASH cancer meeting preview
Detailed data for Genmab's CD20 antibody will be presented at the ASH cancer
meeting on Monday evening (8 December). This is Genmab's lead product which
could be filed within the coming weeks/months and launched in the US next year
with marketing partner GSK.
Impressive headline clinical data for the anti-CD20 antibody in refractory CLL (a
blood cancer) were released in July, and we saw more details when the meeting
abstracts were published last month. Despite some safety signals, the risk/benefit
profile appears favourable taking into account these patients’ late-stage disease,
so the outlook is so far positive for product approval.
We are looking for the following information at ASH which could improve our
outlook for Genmab's CD20: (1) strong efficacy in patients previously exposed to
the commonly used CD20 antibody Rituxan; (2) similar efficacy in patients from
different geographic regions; (3) good duration of response (at least 3-4 months);
and (3) endorsement from clinicians regarding broad use of Genmab's antibody in
other blood cancers despite the safety signals revealed in the current study.
A positive view from clinicians would support our CD20 peak sales forecast of
over $2bn across multiple disease indications.
Erica Whittaker >>
Research Analyst, MLPF&S (UK)
+44 20 7996 2408
Jeg tror også at ASH bliver en trigger for Genmab. Jeg forestår ikke hvad merril mener med Safety Signals? Det er Erica igen der har fundet på noget.
4/12 2008 10:18 Solsen 0
458 Der er mindre saety signals end i andre behandlingsformer - men der er nogle infusionsrelaterede issues. Rituxan, campats etc er blot meget værre !
Men positivt at hun estimerer 2 bn USD.
Fatter ikke der ikke sker noget med kursen ?????
Men positivt at hun estimerer 2 bn USD.
Fatter ikke der ikke sker noget med kursen ?????
4/12 2008 10:26 greed 0459 Ingen tør at tage risk nu - men når vi ser indikationer på hvor sygt dårlige Q4 + Q1 tallene fra industri & retail bliver så kan der måske komme fornyet appetit efter Genmab
Jeg tror også at den næste periode bliver rigtigt svær. Alt står efterhånden meget stille rundt omkring, meget dårlig stemning på direktionsgangene.
Det bliver nok M&A der skal drive aktiemarkedet og derfor kun på enkelte aktier. Nu læser jeg at amagerbanken har svært ved at sælge sig selv. Det er vel danmarks 5te største bank. Det er ikke et godt signal.
Det gode for os er at Genmab netop er en M&A case, samt selvfølgelig også en transformationscase. Hvis Gen IKKE bliver overtaget så tror jeg at 2. halvdel af 2009 bliver en sindssygt gylden periode, når salgstallene begynder at komme ind.
Det er lovende
Det bliver nok M&A der skal drive aktiemarkedet og derfor kun på enkelte aktier. Nu læser jeg at amagerbanken har svært ved at sælge sig selv. Det er vel danmarks 5te største bank. Det er ikke et godt signal.
Det gode for os er at Genmab netop er en M&A case, samt selvfølgelig også en transformationscase. Hvis Gen IKKE bliver overtaget så tror jeg at 2. halvdel af 2009 bliver en sindssygt gylden periode, når salgstallene begynder at komme ind.
Det er lovende
Det er altså som om jeg har været til en anden telekonference end markedet. Jeg ville tro dette kunne have sendt den op imod de 300
4/12 2008 17:57 Solsen 0465 Markedet er helt godnat og blottet for al sund fornuft.
Det gælder ikke kun Genmab - gad vide hvornår de fundamentale sunde virksomheder belønnes ?
Det gælder ikke kun Genmab - gad vide hvornår de fundamentale sunde virksomheder belønnes ?
jeg synes det er så rystende at være vidende til. I min egen lille verden som er afhængig af venturekapital, kan jeg melde at INGEN investerer i noget længere i Danmark.
